Mengya Zhang

Mengya Zhang is a prominent inventor based in Xiamen, China. He has made significant contributions to the field of virology, particularly in the study and treatment of influenza viruses. With a total of 2 patents, his work focuses on innovative solutions for combating influenza infections.

Latest Patents

Mengya Zhang's latest patents include two groundbreaking inventions. The first patent is titled "Mutant of hemagglutinin protein of H3N2 subtype influenza virus and use thereof." This invention relates to a mutant of the hemagglutinin protein, which is crucial for the influenza virus's ability to infect host cells. The patent also covers a pharmaceutical composition, such as a vaccine, that incorporates this mutant, along with methods for its preparation and use in preventing or treating influenza infections.

The second patent is "Broad-spectrum monoclonal anti-flu B antibody and uses thereof." This invention provides a broad-spectrum monoclonal antibody targeting the Flu B virus. It includes cell strains that generate the antibody and a composition containing it. The patent outlines various uses of the antibody for diagnosing, preventing, and treating Flu B infections and related diseases.

Career Highlights

Mengya Zhang is affiliated with Xiamen University, where he conducts his research and development activities. His work has garnered attention for its potential impact on public health, particularly in the context of influenza outbreaks.

Collaborations

Mengya Zhang collaborates with notable colleagues, including Yixin Chen and Chenguang Shen. Their combined expertise enhances the research efforts in the field of influenza virus treatment and prevention.

Conclusion

Mengya Zhang's innovative contributions to influenza research demonstrate his commitment to advancing medical science. His patents reflect a dedication to developing effective solutions for combating viral infections.

Profile summary based on public USPTO records.